KDIGO 2025 常染色体显性多囊肾病临床实践指南概要
KDIGO 2025 首次发布常染色体显性多囊肾病(ADPKD)临床实践指南,涵盖命名、诊断、预后、肾病管理、多囊肝、颅内动脉瘤、生活方式、妊娠、儿科等内容。指南基于系统文献综述与 GRADE 分级,提供可操作推荐与实践要点,并指出证据局限与研究建议。
要点
- 首部 KDIGO ADPKD 指南,覆盖诊断、预后、肾外表现及全程管理。
- 推荐基于系统综述与 GRADE 分级,并附实践要点指导未系统评价领域。
- 明确证据局限并提出研究建议,兼顾政策与支付影响。
核心结论
- KDIGO 2025 发布首部 ADPKD 临床实践指南,为医护与患者提供可操作推荐。
研究设计与样本
- 指南由 KDIGO 制定,基于严谨系统文献综述与 GRADE 分级,联合患者伙伴、临床医生与研究者共同开发。
主要发现
- 指南涵盖命名、诊断、预后、患病率、肾脏表现、CKD 管理与进展、肾衰竭与肾脏替代治疗、延缓进展疗法、多囊肝、颅内动脉瘤及其他肾外表现、生活方式与心理社会、妊娠与生殖、儿科及管理方法。
关键数值与推荐
- 推荐强度采用 GRADE 方法分级,并为未进行系统评价的领域提供实践要点。
临床怎么用
- 指南面向医护、ADPKD 患者及利益相关者,提供可操作推荐与实践要点以指导临床 care。
局限性
- 指南讨论了证据局限性,并提供研究建议以填补知识空白及政策与支付影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal, based on a rigorous, formal systematic literature review. The strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points serving to direct clinical care or activities relating to areas for which a systematic review was not conducted. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, people living with ADPKD, and stakeholders involved in the various aspects of ADPKD care.
引用
- Torres VE, Ahn C, Barten TRM, et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025. PMID: 39848746. doi:10.1016/j.kint.2024.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。